Successful treatment of pyopneumothorax secondary to Streptococcus constellatus infection with linezolid: a case report and review of the literature

Streptococcus constellatus belongs to the Streptococcus milleri group of bacteria, which consists of S. constellatus, Streptococcus intermedius, and Streptococcus anginosus [1]. S. constellatus usually causes abscesses in various organs. Linezolid has not been reported to treat pyopneumothorax caused by S. constellatus infection. Here, we report a case of successful treatment of a patient with pyopneumothorax due to S. constellatus infection. This case contributes valuable information to the current knowledge on the treatment of this infectious disease.

A 55-year-old Han Chinese man was admitted to our hospital on July 26, 2018 on presenting with a chief complaint of fever. Our patient began to have fever 17 days prior to his presentation, and his highest temperature had been 38.5 °C, accompanied by pain in his right chest and cough. He denied symptoms of chest tightness, nausea, and vomiting. He had taken oral amoxicillin without obvious effect, and the symptoms of fever and chest pain continued. He denied hepatitis, tuberculosis, and a history of hypertension or diabetes mellitus.

On admission, a physical examination revealed a temperature of 36.5 °C and blood pressure of 115/70 mmHg with a pulse rate of 75 beats per minute (bpm). A lung examination revealed reduced breath sound in the right lung field. The breath sound in the left lung was clear. A lung computed tomography (CT) scan (July 26, 2018) showed pyopneumothorax of the right lung and lower lobe right lung infection (Fig. 1); a cardiac ultrasound was normal.

Pyopneumothorax is the accumulation of gas and pus in the pleural cavity. Bacteria that frequently cause pyopneumothorax include Pseudomonas aeruginosa, Escherichia coli and Streptococcus [2].

The S. milleri group is a heterogeneous group of Streptococci, which is considered an important pathogen. It consists of three distinct species: S. anginosis, S. constellatus and S. intermedius. S. milleri has emerged in recent years as an organism associated with purulent disease in humans. S. constellatus is usually present in the normal flora of the mouth, vagina, respiratory tract, and gastrointestinal tract [3, 4]. Distinct species have been implicated in a number of pyogenic infections, including soft tissue infection, intra-abdominal and pulmonary abscesses, and central nervous system infections [5]. There is a considerable mortality rate from S. milleri infection. Fernando Cobo reported that the mean age at diagnosis was 62.06 ± 15 years. Two of 12 patients with S. milleri infection died as a consequence of infection. Risk factors for S. milleri infection include alcoholism, chronic obstructive pulmonary disease, and diabetes mellitus. The most frequently used antimicrobials for treatment were ceftriaxone and levofloxacin [5].

Cases of pyopneumothorax secondary to S. milleri infection have rarely been reported [6, 7]. Our case is the third case report of patients with pyopneumothorax caused by S. milleri. The summarization of the three cases are shown in Table 2. The first case was a 37-year-old man with hepatitis C infection. A chest radiograph and CT scan showed a large pleural cavity in the right hemithorax with an air-fluid level. The patient received empiric antibiotic therapy with cefuroxime and clindamycin. The patient recovered upon antibiotic treatment and drainage and was dismissed from the hospital after 17 days to home care [7]. The second patient was a 46-year-old Malay woman with underlying hypothyroidism post thyroidectomy who presented with worsening breathlessness, orthopnea, productive cough, and left-sided pleural chest pain of 3 days’ duration. The patient was treated with antibiotics for a total of 6 weeks and underwent open thoracotomy and decortication during admission [6]. In the current case, infection occurred primarily without any pre-existing pulmonary sequence or long treatment history. The patient was apparently healthy without any history of immunosuppression. However, her blood glucose was higher than normal, and diabetes was diagnosed on admission. The patient had undiagnosed type 2 diabetes before admission to our hospital. A previous study showed that diabetes is a risk factor for S. milleri group infection [5]; therefore, we deduced that the infection might have been related to the rise of blood glucose.

In our case, we did not use cefuroxime and clindamycin as the empirical treatment. A drug sensitivity test showed that S. milleri was sensitive to linezolid, penicillin G, cefotaxime, vancomycin, and cefuroxime. Linezolid can be considered as the first member of the class of oxazolidinone antibiotics. Linezolid has been approved by the Food and Drug Administration for the treatment of the following: Staphylococcus aureus, Streptococcus pneumonia, and vancomycin-resistant Enterococcus faecium (VREF) infections [8]. A previous study also showed that S. constellatus isolated from liver abscesses was also sensitive to linezolid; however, the patient was treated with ceftriaxone [9]. The main side effects of linezolid were hematologic side effects including myelosuppression and thrombocytopenia. The ordinary dose of linezolid was 0.6 g per 12 hours. We had to monitor the blood routine for side effects. Our patient did not show any hematologic side effects and his platelet count was in the normal range.